open access
High-intensity exercise improves pulmonary function and exercise tolerance in a patient with TSC-LAM
open access
Abstract
Introduction: While exercise has been shown to improve respiratory symptoms, exercise tolerance, and bone mineral density in many populations, no supervised exercise training interventions have been undertaken in patients with lymphangioleiomyo-matosis (LAM).
Material and methods: One patient with TSC-LAM (tuberous sclerosis complex lymphangioleiomyomatosis) participated in two weekly sessions (50–60 min) of supervised aerobic exercise at 80–85% heart rate max for one year. Treadmill ergometry (VO2peak), spirometry (FEV1, FVC, FEV1/FVC, peak flow), and bone mineral density testing were performed prior to every 3 months. Results: After one year of supervised aerobic exercise training we saw dramatic increases in the patient’s VO2max (20%), FEV1 (9.5%), FEV1/FVC (9.1%) and peak flow (47%).
Conclusions: The results from this study indicate that supervised exercise training can improve exercise tolerance and pulmonary function in a patient with lymphangioleiomyomatosis. Further research is needed, including longitudinal studies with larger sample sizes, to determine long-term effects and consistency of these findings. Aerobic exercise may offer a viable alternative or com-pliment to pharmacological interventions in the treatment of lymphangioleiomyomatosis. We show that high-intensity exercise training can markedly and safely improve pulmonary function in a patient with TSC-LAM. While we did not record quality of life or mood states, our patient did report improved self-confidence as well as enhanced mood.
Abstract
Introduction: While exercise has been shown to improve respiratory symptoms, exercise tolerance, and bone mineral density in many populations, no supervised exercise training interventions have been undertaken in patients with lymphangioleiomyo-matosis (LAM).
Material and methods: One patient with TSC-LAM (tuberous sclerosis complex lymphangioleiomyomatosis) participated in two weekly sessions (50–60 min) of supervised aerobic exercise at 80–85% heart rate max for one year. Treadmill ergometry (VO2peak), spirometry (FEV1, FVC, FEV1/FVC, peak flow), and bone mineral density testing were performed prior to every 3 months. Results: After one year of supervised aerobic exercise training we saw dramatic increases in the patient’s VO2max (20%), FEV1 (9.5%), FEV1/FVC (9.1%) and peak flow (47%).
Conclusions: The results from this study indicate that supervised exercise training can improve exercise tolerance and pulmonary function in a patient with lymphangioleiomyomatosis. Further research is needed, including longitudinal studies with larger sample sizes, to determine long-term effects and consistency of these findings. Aerobic exercise may offer a viable alternative or com-pliment to pharmacological interventions in the treatment of lymphangioleiomyomatosis. We show that high-intensity exercise training can markedly and safely improve pulmonary function in a patient with TSC-LAM. While we did not record quality of life or mood states, our patient did report improved self-confidence as well as enhanced mood.
Keywords
tuberous sclerosis; exercise; lymphangioleiomyomatosis


Title
High-intensity exercise improves pulmonary function and exercise tolerance in a patient with TSC-LAM
Journal
Advances in Respiratory Medicine
Issue
Article type
Case report
Pages
356-359
Published online
2020-07-27
DOI
10.5603/ARM.a2020.0129
Pubmed
Bibliographic record
Adv Respir Med 2020;88(4):356-359.
Keywords
tuberous sclerosis
exercise
lymphangioleiomyomatosis
Authors
Thomas William Lowder


- Sato T, Seyama K, Kumasaka T, et al. A patient with TSC1 germline mutation whose clinical phenotype was limited to lymphangioleiomyomatosis. J Intern Med. 2004; 256(2): 166–173.
- Cudzilo CJ, Szczesniak RD, Brody AS, et al. Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest. 2013; 144(2): 578–585.
- Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006; 173(1): 105–111.
- Gupta N, Lee HS, Young LR, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011; 364(17): 1595–1606.
- Taillé C, Borie R, Crestani B. Current management of lymphangioleiomyomatosis. Curr Opin Pulm Med. 2011; 17(5): 374–378.
- McCormack FX, Gupta N, Finlay GR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008; 358(2): 140–151.
- Bittmann I, Rolf B, Amann G, et al. Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum Pathol. 2003; 34(1): 95–98.
- Swigris JJ, Lee HS, Cohen M, et al. St. George's Respiratory Questionnaire has longitudinal construct validity in lymphangioleiomyomatosis. Chest. 2013; 143(6): 1671–1678.
- Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005; 2(1): 111–124.
- Westwood M, Bourbeau J, Jones PW, et al. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011; 12: 40.
- Taveira-DaSilva AM, Stylianou MP, Hedin CJ, et al. Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2003; 168(12): 1427–1431.
- Araujo MS, Baldi BG, Freitas CSG, et al. Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial. Eur Respir J. 2016; 47(5): 1452–1460.